1 / 20

Guidance for Industry CGMP for Phase 1 Investigational Drugs

Guidance for Industry CGMP for Phase 1 Investigational Drugs. July 2008 Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Office of Regulatory Affairs (ORA). Introduction. Panel Members: Melissa Morandi, Moderator Zhengtian “Titan” Gu, PhD

tomas
Download Presentation

Guidance for Industry CGMP for Phase 1 Investigational Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Guidance for IndustryCGMP for Phase 1 Investigational Drugs July 2008 Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Office of Regulatory Affairs (ORA)

  2. Introduction • Panel Members: • Melissa Morandi, Moderator • Zhengtian “Titan” Gu, PhD • Lizzie Leininger , PhD • William (Rick) Srigley • Interactive Panel Format • Hold questions until last speaker • Share information about your interpretation and how your company is implementing (or not) the guidance • How will this guidance change Phase 1 manufacturing? • Will it foster more opportunities to get into Phase 1?

  3. Overview: cGMP for Phase 1 • Past: Applied same standard to all drugs that were be administered to humans • July 2008: The manufacture of most investigational new drugs (IND) used in phase 1 clinical trials are exempt from complying with 21 CFR part 211 • Improve the quality of phase 1 investigational drugs and facilitate the initiate of clinical trials in humans

  4. Overview: cGMP for Phase 1 • Other guidance from FDA: • “INDs---Approaches to Complying with CGMP During Phase 1” dated January 2006 is being issued concurrently with a final rule that specifies that 21 CFR part 211 no longer applies for most investigational products, including exploratory products that are manufactured for use in phase 1 • Preamble to 21 CFR 210 and 211 • 505(i) of the FD&C Act

  5. Overview: cGMP for Phase 1 • Included: • Recombinant and non-recombinant products • Vaccines • Allergenic products • In vivo diagnostics • Plasma derivatives Blood and blood components (but must comply with 21 CFR 600-660) • Gene therapy and somatic cellular therapy • APIs used in phase 1 • Excluded: • Human cell or tissue products • Clinical trials for device approval • Products manufactured for phase 1 and 2 clinical trials • Already approved products • PET drugs (21 CFR 212)

  6. Overview: CGMP for Phase 1 • General Points throughout the guideline: • Quality and safety maintained by appropriate QC procedures, Good scientific and QC principles • Well-defined, written procedures • Adequately controlled equipment and manufacturing environment • Accurate and consistently recorded data from manufacturing and testing • Drugs must meet appropriate standards of safety, identity, strength, quality, and purity • Use of the word appropriate ~ 35 times

  7. Facilities • Can use laboratories that are not expressly or solely designed for their manufacture, can use shared facilities, academic institutions • Need to conduct a comprehensive and systematic evaluation of the manufacturing setting to identify potential hazards • Focus on contamination and cross-contamination with other substances • Identify appropriate actions prior to and during manufacturing that eliminate or mitigate those hazards • Assess contract facilities to ensure effective quality control functions • How will we document these assessments?

  8. Equipment • Equipment: Disposables, Prepackaged Materials, Closed Systems (can potentially alleviate the need for stricter room classification…) • “Appropriate” space, lighting, cooling, ventilation, cooling, heating, plumbing, washing, and sanitation • Identify all equipment used for a particular process and document it in the record • Equipment that will not react with, add to, or be absorbed by the phase 1 drug • Equipment properly maintained, cleaned, calibrated and sanitized following written procedures • Procedural controls to prevent contamination and cross contamination • Air cleanliness suitable to the operations “Use of procedural controls in a facility promotes orderly manufacturing and aids in preventing contamination…”

  9. Personnel and the QC Function • Personnel need education, experience and training • Need a written plan that describes the role and responsibilities of the QC function • Examine materials and components • Review and approval of manufacturing and testing procedures and acceptance criteria • Releasing or rejecting batches • Investigating unexpected results or errors • Recommends assigning an individual independent of manufacturing, however…admits that “ in some small operations it may be necessary to have the same individual perform the manufacturing and the QC functions” • Another qualified individual independent of manufacturing must conduct periodic reviews

  10. Materials • Traceable to each batch • Records need: receipt date, quantity of shipment. supplier’s name, lot number, storage conditions, and expiration date • Establish criteria and examine C of A • Identity testing for API (does not mention identity testing as a requirement for other materials)

  11. Documentation • General Records: • Equipment maintenance and calibration • Manufacturing records and analytical test records • Distribution records • QC Function Plan • Component records • Deviations and investigations • Complaints

  12. Documentation • Sufficient records to replicate manufacturing: • Materials • Equipment • Procedures used • Any problems encountered in manufacturing • Record of changes • Record of microbial controls

  13. Laboratory Controls • Scientifically sound: specific, sensitive and accurate (but does not use the word qualification…) • Specifications for known safety-related concerns should be established and met • Personnel verify that equipment is in good working condition (e.g. system suitability) • Stability from date of manufacture through date of last administration

  14. Packaging, Labeling and Distribution • Procedures for product segregation, label reconciliation, verification of operations by a second person, confirmatory laboratory testing and QC review • Distribution record sufficiently detailed to allow traceability and facilitate recall.

  15. Special Manufacturing Situations • Multi-Product Facilities: Periodically evaluate the implemented procedural control for their effectiveness • Biologics: • Testing to reproduce a comparable phase 1 drug, in-process and final product retains for comparison • Equipment and controls for safety-related functions (e.g. viral clearance) • Testing for safety-related purposes (viral loads, bioburden, removal of residual substances, etc.) • Adventitious agent control • Alternate approaches allowed for gene therapy (e.g. one batch per patient)

  16. Aseptic Processing • References FDA “Guidance for Industry: Sterile Drugs Produced by Aseptic Processing-Current Good Manufacturing Practices.”

  17. cGMPs for Phase 1 Other Considerations • Where is the clinical trial? • ICH Q7A • EMEA • Raw material identity testing • Quality Agreements • Quality Unit • Facility • QP Audits, release of lots, and stability extensions • Expectations of other territories • Expectations of potential partners • What else will the material be used for? • Is it a phase 1/phase 2 trial

  18. cGMPs for Phase 1 Other Considerations • Drug device combination products • Need to follow QSR and Design Controls • Quality Systems and documentation: • Use same or different Quality System for Phase 1 • Separate Training for Phase 1 • Assay Qualification • Audit Program • Document Review • Staffing • Additional requirements such as QC plan, hazard assessment, multi-product use periodic assessment of procedural control, • Documentation of scientific rational • Where will phase 2 work be done? Is there enough information to ensure an efficient and successful tech transfer?

  19. Contract Manufacturing and Testing • Different Quality Agreement for phase 1contractors, or Development Agreement or Scope of Work? • Can you use the pilot or non-GMP facility at contractors? (less $$$ and time constraints) • Documentation practices at contractor • Deviation and Change approval practices • Assessment or Audit • Use sites you may have not used previously • New facilities specific to Phase 1

  20. Impact to Timeline? • Flexibility in facilities uses for manufacturing, internal and for contract manufacturing • Flexibility in staffing • Disposable equipment, less cleaning validation and change over time for facilities • Assay qualification • Documentation in the guideline is similar, but more specific in some areas than 21CFR 211

More Related